Comparative Pharmacology
Head-to-head clinical analysis: CYCLAFEM 7 7 7 versus MINZOYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAFEM 7 7 7 versus MINZOYA.
CYCLAFEM 7/7/7 vs MINZOYA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Ethinyl estradiol suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis; norethindrone induces endometrial changes that inhibit implantation and thickens cervical mucus.
Zinc pyrithione is an antimicrobial agent that inhibits fungal growth by disrupting membrane transport and inhibiting mitochondrial function, leading to cell death.
One tablet (norethindrone 0.5 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days, then one tablet (norethindrone 0.75 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days, then one tablet (norethindrone 1 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days. Dispensed in a 21-tablet pack with 7 placebo tablets. For contraception, take one tablet daily at same time each day for 28 days; begin next pack after 28-day cycle.
Intravenous infusion of 300 mg over 30 minutes every 4 weeks.
None Documented
None Documented
Terminal half-life: 5-13 hours (mean 8 hrs); clinical context: supports every-28-day dosing interval for intramuscular depot.
Terminal elimination half-life of 20-30 hours; at steady state after 5-7 days, half-life reflects accumulation for once-daily dosing.
Renal: ~50-60% as conjugated metabolites; Fecal: ~30-40% via bile; <1% unchanged.
Primarily hepatic metabolism with renal excretion of metabolites (50-60% as unchanged drug and conjugates); approximately 30-40% fecal elimination.
Category C
Category C
Oral Contraceptive
Oral Contraceptive